Pediatric oncology and the future of oncological imaging

Pediatric Radiology

Volumn 41, Issue SUPPL. 1, 2011, Pages

  Voss, Stephan D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Diffusion imaging; Molecular imaging; Pediatric cancer; Response assessment

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALGORITHM; CHILDHOOD CANCER; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGING; MOLECULAR THERAPY; NANOMEDICINE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TECHNIQUE; TECHNOLOGY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR;

ALGORITHMS; DIAGNOSTIC IMAGING; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PEDIATRICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955684507     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-011-2008-4     Document Type: Review

References (56)

1. Zubrod C, Schneiderman M, Frei E et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 11:7-33
2. Adamson PC (2009) Imaging in early phase childhood cancer trials. Pediatr Radiol 39(Suppl 1):S38-S41
3. Reaman GH (2009) What, why, and when we image: considerations for diagnostic imaging and clinical research in the Children's Oncology Group. Pediatr Radiol 39(Suppl 1):S42-S45
4. Shankar LK, Van den Abbeele A, Yap J et al (2009) Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res 15:1891-1897
5. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207-214 (Pubitemid 11167383)
6. Kim BY, Rutka JT, Chan WC (2010) Nanomedicine. N Engl J Med 363:2434-2443
7. LaRocque J, Bharali DJ, Mousa SA (2009) Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol 42:358-366
8. Portney NG, Ozkan M (2006) Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 384:620-630 (Pubitemid 43237915)
9. Willmann JK, van Bruggen N, Dinkelborg LM et al (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591-607 (Pubitemid 351927724)
10. Petak I, Schwab R, Orfi L et al (2010) Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 9:523-535
11. Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9:363-366
12. Aebersold R, Auffray C, Baney E et al (2009) Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol Oncol 3:9-17
13. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Suzuki C, Jacobsson H, Hatschek T et al (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329-344
15. Barnacle AM, McHugh K (2006) Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr Blood Cancer 46:127-134 (Pubitemid 43076061)
16. Desar IM, van Herpen CM, van Laarhoven HW et al (2009) Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 35:309-321
17. Portwine C, Marriott C, Barr RD (2010) PET imaging for pediatric oncology: an assessment of the evidence. Pediatr Blood Cancer 55:1048-1061
18. McCarville MB (2009) PET-CT imaging in pediatric oncology. Cancer Imaging 9:35-43
19. Franzius C (2010) FDG-PET/CT in pediatric solid tumors. Q J Nucl Med Mol Imaging 54:401-410
20. Kleis M, Daldrup-Link H, Matthay K et al (2009) Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 36:23-36
21. Furth C, Steffen IG, Amthauer H et al (2009) Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 27:4385-4391
22. Gallamini A, Hutchings M, Avigdor A et al (2008) Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma 49:659-662
23. Hawkins DS, Conrad EU 3rd, Butrynski JE et al (2009) [F-18]- fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115:3519-3525
24. Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828-8834 (Pubitemid 46211529)
25. Weckesser M (2009) Molecular imaging with positron emission tomography in paediatric oncology-FDG and beyond. Pediatr Radiol 39(Suppl 3):450-455
26. Voss SD, Smith SV, DiBartolo N et al (2007) Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci USA 104:17489-17493 (Pubitemid 350219865)
27. Mach RH, Dehdashti F, Wheeler KT (2009) PET radiotracers for imaging the proliferative status of solid tumors. PET Clin 4:1-15
28. Malempati S, Weigel B, Ingle AM et al (2009) A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol 27:15s (suppl; abstr 10013)
29. Heneweer C, Grimm J (2011) Clinical applications in molecular imaging. Pediatr Radiol 41:199-207
30. Pichler BJ, Kolb A, Nagele T et al (2010) PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 51:333-336
31. Judenhofer MS, Wehrl HF, Newport DF et al (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14:459-465 (Pubitemid 351499385)
32. Robbins E (2008) Radiation risks from imaging studies in children with cancer. Pediatr Blood Cancer 51:453-457
33. Alessio AM, Kinahan PE, Manchanda V et al (2009) Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med 50:1570-1577
34. Sauter AW, Wehrl HF, Kolb A et al (2010) Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 16:508-515
35. Wehrl HF, Sauter AW, Judenhofer MS et al (2010) Combined PET/MR imaging-technology and applications. Technol Cancer Res Treat 9:5-20
36. Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102-125
37. Afaq A, Andreou A, Koh DM (2010) Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging 10 Spec no A:S179-S188
38. Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 188:1622-1635
39. Murphy P, Koh DM (2010) Imaging in clinical trials. Cancer Imaging 10 Spec no A:S74-S82
40. Humphries PD, Sebire NJ, SiegelMJ et al (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245:848-854 (Pubitemid 350127356)
41. Kwee TC, Takahara T, Ochiai R et al (2009) Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol 70:409-417
42. Darge K, Jaramillo D, Siegel MJ (2008) Whole-bodyMRI in children: current status and future applications. Eur J Radiol 68:289-298
43. Krohmer S, Sorge I, Krausse A et al (2010) Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol 74:256-261
44. Ladd SC (2009) Whole-body MRI as a screening tool? Eur J Radiol 70:452-462
45. Barrett T, Brechbiel M, Bernardo M et al (2007) MRI of tumor angiogenesis. J Magn Reson Imaging 26:235-249 (Pubitemid 47257720)
46. Hahn OM, Yang C, Medved M et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572-4578
47. Shusterman S, London WB, Gillies SD et al (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 28:4969-4975
48. Miller JC, Thrall JH (2004) Clinical molecular imaging. J Am Coll Radiol 1:4-23 (Pubitemid 40354161)
49. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012-4021
50. Choi HS, Liu W, Liu F et al (2010) Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 5:42-47
51. Troyan SL, Kianzad V, Gibbs-Strauss SL et al (2009) The FLARE intraoperative near-infrared fluorescence imaging system: a first-in- human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 16:2943-2952
52. Begent J, Sebire NJ, Levitt G et al (2011) Pilot study of F(18)- fluorodeoxyglucose positron emission tomography/computerised tomography in Wilms' tumour: correlation with conventional imaging, pathology and immunohistochemistry. Eur J Cancer 47:389-396
53. Sharp SE, Shulkin BL, Gelfand MJ et al (2009) 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 50:1237-1243
54. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
55. Padhani AR, Miles KA (2010) Multiparametric imaging of tumor response to therapy. Radiology 256:348-364
56. Voss SD (2010) Imaging and response assessment in Hodgkin lymphoma. Am Soc Clin Oncol Ed Book, 397-407